ARDS, Human
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Direct BiologicsTX - Austin
1 program1
Bone Marrow Mesenchymal Stem Cell Derived Extracellular VesiclesPhase 1/21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Direct BiologicsBone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles
LongeveronLongeveron Mesenchymal Stem Cells
Clinical Trials (2)
Total enrollment: 70 patients across 2 trials
Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for ARDS
Start: Dec 2024Est. completion: Dec 2024
Phase 1/2Withdrawn
Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)
Start: Jul 2020Est. completion: Jul 202570 patients
Phase 1Unknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space